Evidence map›Paper›PMID 39022073›Full record

ArticleHeliyon2024

Potential preventative impact of aloe-emodin nanoparticles on cerebral stroke-associated myocardial injury by targeting myeloperoxidase: In supporting with

Praveen Kumar Pasala, Niranjan Kumar Raghupathi, Deepak A Yaraguppi, Ranadheer Reddy Challa, Bhaskar Vallamkonda, Sheikh F Ahmad, Yeswanth Chennamsetty, P V Kamala Kumari, Prasanth Dsnbk

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Pharmaceuticals (Basel, Switzerland) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Praveen Kumar PasalaDepartment of Pharmacology, Raghavendra Institute of Pharmaceutical Education and Research, JNTUA, Anantapuramu, Andhra Pradesh, 515721, India.
Niranjan Kumar RaghupathiDepartment of Pharmacology, Santhiram College of Pharmacy, JNTUA, Nandyal, 518112, Andhra Pradesh, India.
Deepak A YaraguppiDepartment of Biotechnology, KLE Technological University, Hubli, Karnataka, 580031, India.
Ranadheer Reddy ChallaDepartment of Formulation and Development, Quotient Sciences, 3080 McCann Farm Dr, Garnet Valley, PA, 19060, USA.
Bhaskar VallamkondaDepartment of Pharmaceutical Analysis, Odin Pharmaceutical LLC, Somerset, NJ, 08873, USA.
Sheikh F AhmadDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.
Yeswanth ChennamsettyDepartment of Pharmacology, Santhiram College of Pharmacy, JNTUA, Nandyal, 518112, Andhra Pradesh, India.
P V Kamala KumariDepartment of Pharmaceutics, Vignan Institute of Pharmaceutical Technology, Duvvada, Visakhapatnam, India.
Prasanth DsnbkSchool of Pharmacy & Technology Management, SVKM's Narsee Monjee Institute of Management Studies (NMIMS), Polepally SEZ, TSIIC, Jadcherla, Mahbubnagar, Hyderabad, 509301, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study examined the potential neuroprotective effects of aloe-emodin (AE) nanoparticles on the cerebral stroke-associated target protein myeloperoxidase (MPO). We investigated the binding interactions between AE and MPO through molecular docking and molecular dynamics simulations. Molecular docking results indicated that AE exhibited a binding energy of -6.9 kcal/mol, whereas it was -7.7 kcal/mol for 2-{[3,5-bis(trifluoromethyl)benzyl]amino}-

Indexed as

Aloe emodinAloe emodin nanoparticlesAntioxidantMolecular dockingMolecular dynamicsMyeloperoxidase

Identifiers

PMID39022073
PMCPMC11253067

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.